The Centers for Medicare and Medicaid Services are being urged to make changes that could improve savings for patients and health care payers, as well as expand patient access to biosimilars.
Patients with hepatocellular carcinoma who took a reduced therapy dose had a lower cumulative pill cost and were less likely to discontinue treatment due to toxicities.
A patient-driven titration regimen demonstrated better HbA1C control without increasing the risk of hypoglycemia than a physician-driven titration regimen in patients with type 2 diabetes.
The National Comprehensive Cancer Network has implemented categories of preference for recommendations within their clinical practice guidelines in oncology.
Clinical pathway development needs to better take into account the patient perspective of cancer care, according to Alan Balch, PhD, in a presentation at the Clinical Pathways Congress.
The US Food and Drug Administration has approved the first ever biosimilar for the treatment of various cancers.
Researchers have identified follow-up care and outcomes disparities for patients with brain metastasis treated with stereotactic radiosurgery in a private hospital compared with those treated in a safety-net hospital.
A recent study investigated the drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.
An international expert group has issued consensus-based recommendations on the use of biosimilars for rheumatologic diseases, focusing on cost, extrapolation, and switching between bio-originators and biosimilars.
Older men with prostate cancer are more likely to be treated with radiation when their doctors own radiation machines - even those who may be too old to benefit from the treatment.